Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Xenon Pharmaceuticals Inc. (XENE:NASDAQ), powered by AI.
Xenon Pharmaceuticals Inc. is currently trading at $51.99. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Xenon Pharmaceuticals Inc. on Alpha Lenz.
Xenon Pharmaceuticals Inc.'s P/E ratio is -11.9.
“Xenon Pharmaceuticals Inc. trades at a P/E of -11.9 (undervalued) with modest ROE of -51.8%.”
Ask for details →Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. The primary function of Xenon Pharmaceuticals is to advance its research and development pipeline of targeted treatment candidates, particularly in areas such as epilepsy and rare neurological conditions. The company is distinguished by its strong emphasis on proprietary technologies and its ability to leverage its expertise in ion channel genetics. Xenon Pharmaceuticals impacts the biotechnology sector by contributing to the understanding and treatment of neurological diseases through its scientific advancements. Based in Canada, the company collaborates with global scientific and medical communities to translate their research into clinical success. By addressing niche therapeutic areas with unmet medical needs, Xenon Pharmaceuticals plays a significant role in the biotech industry, working towards providing patients with more effective treatment options.
“Xenon Pharmaceuticals Inc. trades at a P/E of -11.9 (undervalued) with modest ROE of -51.8%.”
Ask for details →Xenon Pharmaceuticals Inc. (ticker: XENE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 316 employees. Market cap is $4.1B.
The current price is $51.99 with a P/E ratio of -11.91x and P/B of 7.08x.
ROE is -51.76% and operating margin is -4974.27%. Annual revenue is $8M.